SEVERANCE AGREEMENT AND GENERAL RELEASESeverance Agreement • March 6th, 2009 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances)
Contract Type FiledMarch 6th, 2009 Company IndustryThis SEVERANCE AGREEMENT AND GENERAL RELEASE (“Agreement”) is made and entered into by Michael Darwin (“Employee”) and BioCryst Pharmaceuticals, Inc. (“the Company”).
FIRST AMENDMENT TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • March 6th, 2009 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 6th, 2009 Company Industry JurisdictionThis First Amendment (this “Amendment”) to the License, Development and Commercialization Agreement between BioCryst Pharmaceuticals, Inc. (“BioCryst”) and Shionogi & Co., Ltd. (“Shionogi”), dated as of February 28, 2007 (the “Agreement”), shall be effective as of September 30, 2008 (the “First Amendment Date”).